A clinical trial led by NIH researchers revealed that a new form of tumor infiltrating lymphocyte (TIL) therapy combined with the immune checkpoint inhibitor pembrolizumab significantly improved outcomes in patients with metastatic gastrointestinal cancers. About 24% of treated patients saw substantial tumor size reduction, contrasting with only 7.7% who received TILs alone. This advancement could pave the way for addressing a wider range of solid tumors, as the study showcases a potential breakthrough in personalized cancer immunotherapy.
"We see a little crack in the solid wall of cancer by using cell-based immunotherapy for the common solid cancers, and we think we have ways to open that crack even further."
#cancer-immunotherapy #tumor-infiltrating-lymphocytes #metastatic-cancers #clinical-trials #personalized-medicine
Collection
[
|
...
]